Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Dabrafenib With or Without Trametinib in Treating Patients With Recurrent Thyroid Cancer

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
National Comprehensive Cancer Network
Information provided by (Responsible Party):
Manisha Shah, Ohio State University Comprehensive Cancer Center
ClinicalTrials.gov Identifier:
NCT01723202
First received: October 22, 2012
Last updated: October 7, 2016
Last verified: October 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: September 2017 (Final data collection date for primary outcome measure)